ZMYND8, recognized as a core component of various transcriptional regulatory complexes, has demonstrated significant tumor-suppressive effects in breast cancer [40] and prostate cancer [41] in previous studies, providing evidence for its potential as a biomarker candidate in this research. This evidence concerns the gene ZMYND8 and prostate cancer.